Drugs / ASP2074
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05646797 | Feb 2023 → Oct 2024 | cancer | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05646797 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05646797 ↗ |